Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. [electronic resource]
Producer: 20040112Description: 1611-5 p. digitalISSN:- 1078-0432
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Alleles
- Antineoplastic Agents -- therapeutic use
- Capecitabine
- Colorectal Neoplasms -- drug therapy
- DNA, Neoplasm -- genetics
- Deoxycytidine -- analogs & derivatives
- Female
- Fluorouracil -- therapeutic use
- Genotype
- Humans
- Male
- Methylenetetrahydrofolate Reductase (NADPH2) -- genetics
- Middle Aged
- Neoplasm Staging
- Polymorphism, Genetic
- Predictive Value of Tests
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.